SEL24/MEN1703 in Patients With Acute Myeloid Leukemia

Phase I/II, open-label, multi-center, dose escalation study to estimate the maximum tolerated
dose of SEL24/MEN1703 in patients with Acute Myeloid Leukemia.

The clinical trial will investigate the safety profile and anti-leukemic activity of
SEL24/MEN1703 in patients with Acute Myeloid Leukemia and that have no standard therapeutic
options available.

The clinical trial encompasses two parts:

- Part 1, ascending dose levels: the main purpose of this part of the clinical trial is to
determine the highest dose of SEL24/MEN1703 considered to be well tolerated.

- Part 2, expansion cohort: the main purpose of this part of the clinical trial is to
assess the safety and anti-leukemia activity of SEL24/MEN1703 given at the highest
tolerated dose in patient with Acute Myeloid Leukemia.

Patients participating to the clinical trial will take the study drug as oral capsules once
every 14 days over 21-day cycle.

Inclusion Criteria:

- patients with diagnosis of Acute Myeloid Leukemia

- patients has no standard therapeutic options (newly diagnosed Acute Myeloid Leukemia;
Relapsed Acute Myeloid Leukemia ans Primary Refractory Acute Myeloid Leukemia).

Exclusion Criteria:

- anti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal
therapy, biologic, immunotherapy or investigational drugs) received within 14 days or
5 half-lives for targeted therapies (whichever is shorter) before first dose of study
drug (to be supplemented)